Point72 Middle East FZE’s Immunovant IMVT Stock Holding History

Point72 Middle East FZE’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,272	Closed	-$349K	–	644
2023 Q4	$349K	Buy	+8,272	New	+$304K	0.01%	919
2023 Q3	–	Sell	-48,077	Closed	-$912K	–	1646
2023 Q2	$912K	Buy	48,077 +41,461	+627%	+$773K	0.03%	615
2023 Q1	$103K	Buy	+6,616	New	+$115K	﹤0.01%	1121

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Middle East FZE's IMVT Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 8,272 shares — an estimated $349K sold.

Point72 Middle East FZE first reported a position in IMVT in Q1 2023 and held it in 3 quarters. The position peaked at $912K in Q2 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

Point72 Middle East FZE reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
Point72 Middle East FZE sold 8,272 Immunovant shares in Q1 2024, an estimated $349K.
Point72 Middle East FZE first reported a position in Immunovant in Q1 2023 and held it in 3 quarters.
Point72 Middle East FZE's Immunovant position peaked at $912K in Q2 2023.
209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.